McIlwain Matthew S
Known title: DirectorCIK: 0001381752
McIlwain Matthew S's purchase track record
McIlwain Matthew S has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/15/2021 | NAUT | $530K | -26.9% | -29.1% | -14.4% |
| 8/24/2021 | NAUT | $285K | -41.7% | -53.5% | -4.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NAUT | ▲ Buy | Open Market | 100,000 | $530K | 11/15/2021 | View on chart |
| NAUT | ▲ Buy | Open Market | 11,709 | $90K | 8/26/2021 | View on chart |
| NAUT | ▲ Buy | Open Market | 11,693 | $90K | 8/25/2021 | View on chart |
| NAUT | ▲ Buy | Open Market | 13,568 | $104K | 8/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Roth Capital initiates coverage on NAUT with $3.50 target
Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.
Roth Capital initiates coverage on NAUT with $3.50 target. Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.